Biohaven reports six partial responses with its FGFR3-targeted ADC BHV-1530 in Phase 1, including patients with advanced urothelial and HPV-positive cancers.
Written By: Aasritha Thippavajjala, PharmD
Reviewed By: Pharmacally Editorial Team
Biohaven has reported preliminary clinical findings from its ongoing Phase 1 study of BHV-1530, an investigational fibroblast growth factor receptor 3 (FGFR3)-directed antibody-drug conjugate (ADC) incorporating its proprietary topoisomerase I (TopoIx) payload. Presented during a plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), the findings showed partial responses in patients with advanced urothelial cancer (UC) and head and neck squamous cell carcinoma (HNSCC).
Unlike conventional FGFR tyrosine kinase inhibitors (TKIs), which block receptor signalling, BHV-1530 is designed to bind FGFR3 on tumour cells, undergo internalisation and deliver its cytotoxic payload intracellularly. This approach does not depend on inhibiting the receptor’s kinase activity.
BHV1530-101: Study Design and Patient Characteristics
BHV1530-101 (NCT06874335) is an ongoing, first-in-human, multicentre Phase 1 study evaluating BHV-1530 as monotherapy and in combination with anti-PD-1 therapy in adults with advanced solid tumours.
At the October 19, 2026 data cutoff, 30 patients had received monotherapy every three weeks at doses ranging from 1.0 to 12.0 mg/kg. Dose escalation remained ongoing, and enrolled patients had received a median of two previous lines of treatment for advanced disease. All patients with UC had previously progressed following enfortumab vedotin plus pembrolizumab (EV+P).
Patients with UC, HNSCC or non-small cell lung cancer (NSCLC) could enrol irrespective of FGFR3 alteration status, without a minimum FGFR3 expression threshold. Patients with other solid tumours required activating FGFR3 alterations.
Antitumour Activity Across FGFR3-Altered Tumours
Of the 30 treated patients, the primary efficacy analysis focused on 10 efficacy-evaluable patients harbouring activating FGFR3 alterations who received doses of 3.3 mg/kg or higher (excluding patients treated at sub-therapeutic dose levels, those with FGFR3 wild-type tumours, or those awaiting their first post-baseline assessment). Among these 10 patients, nine experienced tumour reductions and six achieved partial responses (PRs) comprising both confirmed and unconfirmed responses according to investigator assessments under RECIST v1.1.
Responses occurred in tumours harbouring both FGFR3 mutations and fusions. Specifically, three of five patients with FGFR3-altered UC and all three patients with FGFR3-altered, HPV-positive HNSCC achieved PRs. All responders remained on treatment at the data cutoff, with some continuing beyond six months.
Outside the primary FGFR3-altered cohort, Biohaven also reported tumour reductions in two efficacy-evaluable patients with FGFR3 wild-type UC treated at 3.3 mg/kg or higher, including one PR pending confirmation. One responder in the UC subgroup had previously received an FGFR inhibitor in addition to EV+P.
A notable response occurred in a heavily pretreated patient with HPV-positive metastatic HNSCC harbouring an FGFR3 S249C mutation. Following four previous lines of therapy, including chemoradiation, platinum-based chemotherapy and immunotherapy, the patient achieved a confirmed PR. Target lesions decreased by 67% at Week 6, with the reduction deepening to 86% by Week 24. The patient remained on treatment beyond six months without reported treatment-related adverse events (TRAEs).
Safety Profile and Pharmacokinetic Findings
BHV-1530 was well tolerated across the evaluated dose levels. Among all 30 treated patients, no dose-limiting toxicities (DLTs), treatment-related serious adverse events or treatment-related deaths were reported.
The most common adverse events across the safety population were nausea (43%) and fatigue (37%), all Grade 1 or 2. Haematological toxicities were predominantly low grade and manageable. Notably, no cases of hyperphosphataemia, nail dystrophy, central serous retinopathy or interstitial lung disease (ILD) were observed.
These safety observations are clinically relevant across both the target and payload classes: hyperphosphataemia, nail disorders, stomatitis and retinal toxicities are recognised class-related adverse effects of approved FGFR inhibitors, whereas ILD and severe cytopenias are closely monitored toxicities associated with topoisomerase I inhibitor-based ADCs. However, this early-phase dataset does not establish a comparative safety advantage over existing therapies.
Pharmacokinetic analyses showed that BHV-1530 remained stable in circulation, with free payload exposure below 1% of total ADC exposure. Its reported half-life ranged from 7 to 14 days, supporting the continued investigation of once-every-three-weeks dosing.
Clinical Interpretation
The findings provide an early clinical signal for BHV-1530 in heavily pretreated patients, particularly those with FGFR3-altered UC and HPV-positive HNSCC. The responses observed following EV+P progression are noteworthy given the limited treatment options available in post-checkpoint, post-ADC advanced UC.
Preliminary activity in FGFR3 wild-type UC also warrants further investigation. However, tumour reductions in two patients are insufficient to establish wild-type FGFR3 expression as a predictive biomarker.
Biohaven has initiated combination cohorts evaluating BHV-1530 with anti-PD-1 therapy, including cemiplimab (Libtayo), under a clinical supply agreement with Regeneron Pharmaceuticals. Following a Type C meeting with the US Food and Drug Administration (FDA), the company plans to initiate a pivotal study in FGFR3-altered tumours, beginning with UC, as early as the first half of 2027 to support a potential accelerated approval application.
Although encouraging, these findings remain preliminary. The small efficacy-evaluable population, inclusion of unconfirmed responses, and ongoing dose escalation mean that larger, longer-term studies are needed to establish response durability, optimal dosing and long-term safety.
References
Biohaven’s Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026. 19 November 2026.
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors. NCT06874335.
Biohaven’s Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026. 28 September 2026.
About the Writer
Aasritha Thippavajjala (Linkedin) is a pharm D student and aspiring medical writer with medical writing, clinical training experience and a strong interest in clinical research and patient safety She has hands-on exposure to clinical pharmacy activities including medication profile assessment, clinical case review, identification of potential drug-related problems, ADR awareness, patient counselling, and clinical documentation. She has also gained experience in medical literature review, evidence synthesis, and scientific communication through her published review article on digital twin-based patient simulation and her poster presentation at the 74th Indian Pharmaceutical Congress. Certified in ICH Good Clinical Practice (E6(R3)) and Scientific Writing in Health Research, she is passionate about applying her clinical knowledge and research skills to medical writing ,clinical research and contributing to accurate, evidence-based healthcare.
